JP5980236B2 - ジアミノピリミジン誘導体及びその製造方法 - Google Patents

ジアミノピリミジン誘導体及びその製造方法 Download PDF

Info

Publication number
JP5980236B2
JP5980236B2 JP2013555368A JP2013555368A JP5980236B2 JP 5980236 B2 JP5980236 B2 JP 5980236B2 JP 2013555368 A JP2013555368 A JP 2013555368A JP 2013555368 A JP2013555368 A JP 2013555368A JP 5980236 B2 JP5980236 B2 JP 5980236B2
Authority
JP
Japan
Prior art keywords
propylpyrimidin
group
piperidin
amine
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013555368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506591A (ja
Inventor
イ,ヒョンジュ
キム,ドンフン
キム,テギュン
ユン,ヨンエ
シム,ジェヨン
チャ,ミョンフン
ジュン,ウンジョン
アン,キョンギュ
リ,タイウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of JP2014506591A publication Critical patent/JP2014506591A/ja
Application granted granted Critical
Publication of JP5980236B2 publication Critical patent/JP5980236B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2013555368A 2011-02-25 2012-02-24 ジアミノピリミジン誘導体及びその製造方法 Active JP5980236B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20110016981 2011-02-25
KR10-2011-0016981 2011-02-25
PCT/KR2012/001423 WO2012115478A2 (en) 2011-02-25 2012-02-24 Diaminopyrimidine derivatives and processes for the preparation thereof

Publications (2)

Publication Number Publication Date
JP2014506591A JP2014506591A (ja) 2014-03-17
JP5980236B2 true JP5980236B2 (ja) 2016-08-31

Family

ID=46721361

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013555368A Active JP5980236B2 (ja) 2011-02-25 2012-02-24 ジアミノピリミジン誘導体及びその製造方法
JP2013555369A Active JP5890436B2 (ja) 2011-02-25 2012-02-24 ジアミノピリミジン誘導体及びその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013555369A Active JP5890436B2 (ja) 2011-02-25 2012-02-24 ジアミノピリミジン誘導体及びその製造方法

Country Status (17)

Country Link
US (4) US9850227B2 (enExample)
EP (2) EP2678332B1 (enExample)
JP (2) JP5980236B2 (enExample)
KR (2) KR101671341B1 (enExample)
CN (2) CN103402997B (enExample)
AU (2) AU2012221925B2 (enExample)
BR (2) BR112013019942B1 (enExample)
CA (2) CA2827072C (enExample)
DK (1) DK2678332T3 (enExample)
ES (2) ES2587304T3 (enExample)
HU (1) HUE029988T2 (enExample)
IN (1) IN2013MN01519A (enExample)
MX (2) MX336155B (enExample)
PL (2) PL2678331T3 (enExample)
PT (1) PT2678332T (enExample)
RU (1) RU2587493C2 (enExample)
WO (2) WO2012115478A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2587304T3 (es) * 2011-02-25 2016-10-21 Yuhan Corporation Derivados de diaminopirimidina y procedimientos para la preparación de los mismos
PH12015501130B1 (en) 2012-11-21 2023-01-27 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
KR101657616B1 (ko) * 2013-05-24 2016-09-19 주식회사유한양행 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법
MX370588B (es) * 2013-08-30 2019-12-16 Ptc Therapeutics Inc Inhibidores de la bmi-1 de pirimidina sustituida.
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
CN104003944B (zh) * 2014-05-29 2016-08-24 西北师范大学 一种嘧菌胺的制备方法
EP3929190B1 (en) * 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN105646321A (zh) * 2016-01-07 2016-06-08 中国药科大学 (s)-3-羟基吡咯烷盐酸盐的制备方法
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
KR102441327B1 (ko) * 2018-05-18 2022-09-07 주식회사유한양행 다이아미노피리미딘 유도체 또는 이의 산부가염의 신규의 제조방법
JP2021535198A (ja) 2018-08-17 2021-12-16 ピーティーシー セラピューティクス, インコーポレイテッド 膵臓癌を治療する方法
CA3122182A1 (en) 2018-12-18 2020-06-25 Astrazeneca Ab Pharmaceutical process and intermediates
CN110317176A (zh) * 2019-07-04 2019-10-11 沈阳药科大学 2-氨基嘧啶类化合物及其用途
KR20220006776A (ko) * 2020-07-09 2022-01-18 주식회사유한양행 다이아미노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물 및 이의 제조방법
WO2025104079A1 (en) * 2023-11-17 2025-05-22 Helmholtz-Zentrum für Infektionsforschung GmbH Salicylic acid and picolinic acid derivatives as inhibitors of energy coupling factor (ecf) transporters for the treatment of bacterial infections
WO2026061469A1 (zh) * 2024-09-19 2026-03-26 马应龙药业集团股份有限公司 杂芳胺类化合物、其药物组合物及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CZ284687B6 (cs) 1986-04-30 1999-02-17 Dainippon Pharmaceutical Co., Ltd. Substituovaný benzamidový derivát, způsob jeho výroby a farmaceutický prostředek na jeho bázi
GB9005014D0 (en) 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
JP3398152B2 (ja) * 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー 1n−アルキル−n−アリールピリミジンアミンおよびその誘導体
NZ274978A (en) * 1993-10-12 1998-04-27 Du Pont Merck Pharma 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof
IL112024A (en) 1993-12-21 1999-07-14 Novo Nordisk As Pharmaceutical compositions comprising tetrahydropyridine derivatives substituted with oxadiazole or thiadiazole for treating gastrointestinal motility disorders
EP0775120B1 (en) 1994-08-13 2003-06-04 Yuhan Corporation Novel pyrimidine derivatives and processes for the preparation thereof
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
IN188411B (enExample) * 1997-03-27 2002-09-21 Yuhan Corp
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
KR20060052806A (ko) * 2003-07-25 2006-05-19 시바 스폐셜티 케미칼스 홀딩 인코포레이티드 항균제로서 치환된 2,4-비스(알킬아미노)피리미딘 또는-퀴나졸린의 용도
CA2537182A1 (en) * 2003-08-29 2005-03-10 Dynogen Pharmaceuticals, Inc. Compositions useful for treating gastrointestinal motility disorders
US20060057972A1 (en) 2004-09-14 2006-03-16 Wikel Harold L Adapter for a modular wireless communication device
US20060128726A1 (en) * 2004-11-24 2006-06-15 Xuebao Wang Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulations
US8816090B2 (en) 2005-02-25 2014-08-26 Pfizer Inc. Benzisoxazole derivatives
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
US20080293942A1 (en) * 2005-11-28 2008-11-27 Cousins Russell D Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives
EP2003131A4 (en) * 2006-04-04 2009-12-16 Taisho Pharmaceutical Co Ltd AMINOPYRROLIDINE COMPOUND
EP2007754A1 (en) * 2006-04-10 2008-12-31 Boehringer Ingelheim International GmbH 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer
KR101247840B1 (ko) * 2008-02-22 2013-03-26 에프. 호프만-라 로슈 아게 아밀로이드 베타 조절제
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Egfr 억제제 및 질환 치료방법
ES2587304T3 (es) * 2011-02-25 2016-10-21 Yuhan Corporation Derivados de diaminopirimidina y procedimientos para la preparación de los mismos

Also Published As

Publication number Publication date
HK1188214A1 (zh) 2014-04-25
AU2012221925B2 (en) 2016-05-05
ES2587304T3 (es) 2016-10-21
CN103391935B (zh) 2015-12-23
CA2827030C (en) 2019-01-08
CN103402997A (zh) 2013-11-20
US10640490B2 (en) 2020-05-05
MX2013009549A (es) 2013-09-06
MX337477B (es) 2016-03-07
AU2012221927B2 (en) 2016-04-28
BR112013019942A2 (pt) 2018-08-14
RU2587493C2 (ru) 2016-06-20
EP2678332A2 (en) 2014-01-01
WO2012115480A3 (en) 2012-10-18
BR112013020641B1 (pt) 2021-11-03
KR101671341B1 (ko) 2016-11-01
EP2678331A4 (en) 2014-07-30
RU2013142188A (ru) 2015-03-27
PL2678332T3 (pl) 2016-12-30
BR112013019942B1 (pt) 2022-01-11
IN2013MN01519A (enExample) 2015-06-12
MX2013009627A (es) 2014-02-17
US10227330B2 (en) 2019-03-12
US9850227B2 (en) 2017-12-26
US20180072705A1 (en) 2018-03-15
EP2678332B1 (en) 2016-05-18
WO2012115480A2 (en) 2012-08-30
CN103402997B (zh) 2015-08-26
KR20120098483A (ko) 2012-09-05
KR101671348B1 (ko) 2016-11-01
US20150274700A2 (en) 2015-10-01
CA2827072C (en) 2019-01-08
HK1188215A1 (en) 2014-04-25
JP2014506592A (ja) 2014-03-17
EP2678331A2 (en) 2014-01-01
US9890138B2 (en) 2018-02-13
WO2012115478A2 (en) 2012-08-30
HUE029988T2 (en) 2017-04-28
ES2579830T3 (es) 2016-08-17
RU2013142187A (ru) 2015-03-27
DK2678332T3 (en) 2016-08-15
MX336155B (es) 2016-01-07
CA2827030A1 (en) 2012-08-30
EP2678332A4 (en) 2014-07-23
US20130338179A1 (en) 2013-12-19
BR112013020641A2 (pt) 2016-10-18
US20180111918A1 (en) 2018-04-26
CA2827072A1 (en) 2012-08-30
WO2012115478A3 (en) 2012-10-18
JP2014506591A (ja) 2014-03-17
PT2678332T (pt) 2016-08-22
US20130331377A1 (en) 2013-12-12
EP2678331B1 (en) 2016-04-27
CN103391935A (zh) 2013-11-13
PL2678331T3 (pl) 2016-12-30
JP5890436B2 (ja) 2016-03-22
KR20120098484A (ko) 2012-09-05

Similar Documents

Publication Publication Date Title
CN103391935B (zh) 二氨基嘧啶衍生物及其制备方法
TWI833773B (zh) 化合物
CN1093858C (zh) 用于治疗、特别是治疗良性前列腺增生的喹啉和喹唑啉化合物
US20110021495A1 (en) Quinazoles useful as modulators of ion channels
HU230787B1 (en) Quinolinone derivatives as tyrosine kinase inhibitors
CN101272685A (zh) 包含二芳基胺的化合物和组合物以及它们作为c-kit受体调节剂的用途
CN1784391B (zh) 可用作离子通道调控剂的喹唑啉
HK1188214B (en) Diaminopyrimidine derivatives and processes for the preparation thereof
RU2587981C2 (ru) Производные диаминопиримидина и способы их получения
CN105452238A (zh) 含嘧啶环的二环衍生物及其制备方法
HK1188215B (en) Diaminopyrimidine derivatives and processes for the preparation thereof
JPWO1999055674A1 (ja) 1−[(1−置換−4−ピペリジニル)メチル]−4−ピペリジン誘導体、その製造方法、それを含有する医薬組成物および該化合物の中間体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160726

R150 Certificate of patent or registration of utility model

Ref document number: 5980236

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250